The role of phosphodiesterase isoforms 2, 5, and 9 in the regulation of NO-dependent and NO-independent cGMP production in the rat cervical spinal cord

Journal of Chemical Neuroanatomy

Volumn 31, Issue 4, 2006, Pages 275-303

  de Vente, J ^a   Markerink van Ittersum, M ^a   Vles, J S H ^b  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

cGMP; Micropharmacology; Nitric oxide; Nociception; Phosphodiesterase; Spinal cord

Indexed keywords

2 (3,4 DIMETHOXYBENZYL) 7 [1 (1 HYDROXYETHYL) 4 PHENYLBUTYL] 5 METHYLIMIDAZO[5,1 F][1,2,4]TRIAZIN 4(3H) ONE; 3,3 BIS(2 AMINOETHYL) 1 HYDROXY 2 OXOTRIAZENE; 8 METHOXYISOBUTYLMETHYLXANTHINE; 9 (2 HYDROXY 3 NONYL)ADENINE; BIOLOGICAL MARKER; CALCITONIN GENE RELATED PEPTIDE; CYCLIC GMP; DIPYRIDAMOLE; GLUTAMATE TRANSPORTER; ISOBUTYLMETHYLXANTHINE; ISOENZYME; LECTIN; NITRIC OXIDE; NITRIC OXIDE DONOR; PHOSPHODIESTERASE; PHOSPHODIESTERASE 10; PHOSPHODIESTERASE 2; PHOSPHODIESTERASE 9; PHOSPHODIESTERASE I; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV INHIBITOR; PHOSPHODIESTERASE V; PHOSPHODIESTERASE V INHIBITOR; ROLIPRAM; SCH 81566; SILDENAFIL; SPLEEN EXONUCLEASE; SUBSTANCE P; SYNAPTOPHYSIN; UNCLASSIFIED DRUG; VESICULAR TRANSPORT PROTEIN;

ANIMAL TISSUE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL FUNCTION; CELL SIZE; CELL STIMULATION; CELL STRUCTURE; CELL SUBPOPULATION; CELLULAR DISTRIBUTION; CERVICAL SPINAL CORD; CHOLINERGIC NERVE; CONTROLLED STUDY; DORSAL ROOT; ENZYME ACTIVITY; ENZYME REGULATION; EPENDYMA CELL; GRAY MATTER; IMMUNOREACTIVITY; INCUBATION TIME; INTERNEURON; MALE; MOTONEURON; NERVE ENDING; NERVE FIBER; NEUROCHEMISTRY; NOCICEPTION; NONHUMAN; NUCLEOTIDE METABOLISM; NUCLEOTIDE SEQUENCE; POSTSYNAPTIC MEMBRANE; PRIORITY JOURNAL; PROPRIOCEPTION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RAT; SIGNAL PROCESSING; SPINAL CORD DORSAL HORN; TISSUE DISTRIBUTION; TISSUE SECTION; TISSUE SLICE; VERTEBRAL CANAL;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; 3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ANIMALS; BIOLOGICAL MARKERS; CERVICAL VERTEBRAE; CYCLIC GMP; ENZYME INHIBITORS; IMMUNOHISTOCHEMISTRY; MALE; NERVE TISSUE PROTEINS; NEURONS; NEUROTRANSMITTER AGENTS; NITRIC OXIDE; NITRIC OXIDE DONORS; PAIN; PHOSPHORIC DIESTER HYDROLASES; PLANT LECTINS; PRESYNAPTIC TERMINALS; PROTEIN ISOFORMS; RATS; RATS, INBRED LEW; SIGNAL TRANSDUCTION; SPINAL CORD;

EID: 33646366904     PISSN: 08910618     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchemneu.2006.02.006     Document Type: Article

References (109)

1. Alonso J.R., Arévalo R., Weruaga E., Porteros A., Briñón J.G., and Aijón J. Comparative and developmental neuroanatomical aspects of the NO system. In: Steinbusch H.W.M., de Vente J., and Vincent S.R. (Eds). Handbook of Chemical Neuroanatomy, vol. 17: Functional Neuroanatomy of the Nitric Oxide System (2000), Elsevier Science B.V. 51-109
2. Alvarez F.J., Villalba R.M., Zerda R., and Schneider S.P. Vesicular glutamate transporters in the spinal cord, with special reference to sensory primary afferent synapses. J. Comp. Neurol. 472 (2004) 257-280
3. Andreeva S.G., Dikkes P., Epstein P.M., and Rosenberg P.A. Expression of cGMP-specific phosphodiesterase 9A mRNA in the rat brain. J. Neurosci. 21 (2001) 9068-9076
4. 3H-d-aspartate in the dorsal horn of the rat spinal cord. J. Comp. Neurol. 314 (1991) 114-124
5. Arvidsson U., Riedl M., Elde R., and Meister B. Vesicular acetylcholine transporter (VAchT) protein: a novel and unique marker for cholinergic neurons in the central and peripheral nervous system. J. Comp. Neurol. 378 (1997) 454-467
6. Beavo J.A. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol. Rev. 75 (1995) 725-748
7. Becker E.M., Alonso-Alija C., Apeler H., Gerzer R., Minuth T., Pleiss U., Schmidt P., Schramm M., Schröder H., Schroeder W., Steinke W., Straub A., and Stasch J.P. NO-independent regulatory site of direct sGC stimulators like YC-1 and BAY 41-2272. BMC Pharmacol. 1 (2001) 13
8. Behrends S., Kempfert J., Mietens A., Koglin M., Scholz H., and Middendorff R. Developmental changes of nitric oxide-sensitive guanylyl cyclase expression in pulmonary arteries. Biochem. Biophys. Res. Commun. 283 (2001) 883-887
9. Bellamy T.C., and Garthwaite J. cAMP-specific phosphodiesterase contributes to cGMP degradation in cerebellar cells exposed to nitric oxide. Mol. Pharmacol. 59 (2001) 54-61
10. Blottner, D., Baumgarten, H.G., 1992. Nitric oxide synthetase (NOS)-containing sympathoadrenal cholinergic neurons of the rat IML-cell column: evidence from histochemistry, immunohistochemistry, and retrograde labeling. J. Comp. Neurol. 316, 45-55.
11. Blount M.A., Beasley A., Zoraghi R., Sekhar K.R., Bessay E.P., Francis S.H., and Corbin J.D. Binding of tritiated sildenafil, tadalafil, or vardenafil to the phopshodiesterase-5 catalytic site displays potency, specificity, heterogeneity, and cGMP stimulation. Mol. Pharmacol. 66 (2004) 144-152
12. Boess F.G., Hendrix M., Van der Staay F.J., Erb C., Schreiber R., Van Staveren W., De Vente J., Prickaerts J., Blokland A., and Koenig G. Inhibition of phosphodiesterase 2 increases neuronal cGMP, synaptic plasticity and memory performance. Neuropharmacology 47 (2004) 1081-1092
13. Bredt D.S., Hwang P.M., and Snyder S.H. Localization of nitric oxide synthase indicating a neural role for nitric oxide. Nature 347 (1990) 768-770
14. Cary S.P.L., Winger J.A., and Marletta M.A. Tonic and acute nitric oxide signaling through soluble guanylate cyclase is mediated by nonheme nitric oxide, ATP, and GTP. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 13064-13069
15. Bucle D.R., Arch J.R.S., Connolly B.J., Fenwick A.E., Foster K.A., Murray K.J., Readshaw S.A., Smallridge M., and Smith D.G. Inhibition of cyclic nucleotide phosphodiesterase by derivatives of 1,30bis(cyclopropylmethyl)xanthine. Med. Chem. 37 (1994) 476-485
16. Clapham J.C., and Wilderspin A.F. Cloning of dog heart PDE1A-a first detailed characterization at the molecular level in this species. Gene 268 (2001) 165-171
17. Clowry G.J. Axotomy induces NADPH diaphorase activity in neonatal but not adult motoneurones. Neuroreport 5 (1993) 361-364
18. Conti M., and Jin S.L.C. The molecular biology of cyclic nucleotide phosphodiesterases. Prog. Nucleic Acid Res. 63 (1999) 1-38
19. Denninger J.W., and Marletta M.W. Guanylate cyclase and NO/cGMP signaling pathway. Biochim. Biophys. Acta 1411 (1999) 334-350
20. De Vente J., Steinbusch H.W.M., and Schipper J. A new approach to immunocytochemistry of 3′,5′-cyclic guanosine monophosphate: preparation, specificity, and initial application of a new antiserum against formaldehyde-fixed 3′,5′-cyclic guanosine monophosphate. Neuroscience 22 (1987) 361-373
21. De Vente J., Hopkins D.A., Markerink-van Ittersum M., Emson P.C., Schmidt H.H.H.W., and Steinbusch H.W.M. Distribution of nitric oxide synthase and nitric oxide-receptive, cyclic GMP-producing structures in the rat brain. Neuroscience 87 (1998) 207-241
22. De Vente J., and Steinbusch H.W.M. Nitric oxide-cGMP signaling in the brain. In: Steinbusch H.W.M., de Vente J., and Vincent S.R. (Eds). Handbook of Chemical Neuroanatomy vol. 17 (2000), Elsevier 355-415
23. Duggan A.W., Hendry I.A., Morton C.R., Hutchinson W.D., and Zhao Z.Q. Cutaneous stimuli releasing immunoreactive substance P in the dorsal horn of the cat. Brain Res. 451 (1988) 261-273
24. Dun N.J., Dun S.L., Wu S.Y., Förstermann U., Schmidt H.H.H.W., and Tseng L.F. Nitric oxide synthase immunoreactivity in the rat, mouse, cat and squirrel monkey spinal cord. Neuroscience 54 (1993) 845-857
25. Estévez A.G., Kamaid A., Thompson J.A., Cornwell T.L., Radi R., Barbeito L., and Beckman J.S. Cyclic guanosine 5′ monophosphate (cGMP) prevents expression of neuronal nitric oxide synthase and apoptosis in motor neurons deprived of trophic factors in rats. Neurosci. Lett. 326 (2002) 201-205
26. Estrade M., Grondin P., Cluzel J., Bonhomme B., and Doly M. Effect of a cGMP-specific phosphodiesterase inhibitor on retinal function. Eur. J. Pharmacol. 352 (1998) 157-163
27. Feng-Chen K.C., and Wolpaw J.R. Operant conditioning of H-reflex changes synaptic terminals on primate motoneurons. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 9206-9211
28. Ferreira J., Santos A.R.S., and Calixto J.B. The role of systemic, spinal and supraspinal l-arginine-nitric oxide-cGMP pathway in thermal hyperalgesia caused by intrathecal injection of glutamate in mice. Neuropharmacology 38 (1999) 835-842
29. Fisher D.A., Smith J.F., Pillar J.S., St. Denis S.H., and Cheng J.B. Isolation and characterization of PDE9A, a novel human cGMP-specific phosphodiesterase. J. Biol. Chem. 273 (1998) 15559-15564
30. Francis S.H., Turko I.V., and Corbin J.D. Cyclic nucleotide phosphodiesterases: relating structure and function. Prog. Nucleic Acid Res. 65 (2001) 1-52
31. Friebe A., and Koesling D. Regulation of nitric oxide-sensitive guanylyl cyclase. Circ. Res. 93 (2003) 96-105
32. Fujishige K., Kotera J., Michibata H., Yuasa K., Takebayashi S., Okumuro K., and Omori K. Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP (PDE10A). J. Biol. Chem. 274 (1999) 18438-18445
33. Fujishige K., Kotera J., and Omori K. Striatum- and tstis-specific phosphodiesterase PDE10A. Isolation and characterization of a rat PDE10A. Eur. J. Biochem. 266 (1999) 1118-1127
34. Furuta a., Rothstein J.D., and Martin L.J. Glutamate transporter protein subtypes are expressed differentially during rat CNS development. J. Neurosci. 17 (1997) 8363-8375
35. Garry M.G., Durnett-Richardson J., and Hargreaves K.M. Sodium nitroprusside evokes the release of immunoreactive calcitonin gene-related peptide and substance P from dorsal horn slices via nitric oxide-dependent and nitric oxide-independent mechanisms. J. Neurosci. 14 (1994) 4329-4337
36. Gibson A. Phosphodiesterase 5 inhibitors and nitrergic transmission-from zaprinast to sildenafil. Eur. J. Pharmacol. 411 (2001) 1-10
37. Hawkins R.D., Son H., and Arancio O. Nitric oxide as a retrograde messenger during long-term potentiation in hippocampus. Prog. Brain Res. 118 (1998) 166-172
38. He X.H., Tay S.S.W., and Ling E.A. Expression of NADPH-diaphorase and nitric oxide synthase in lumbosacral motoneurons after knee joint immobilisation in the guinea pig. J. Anat. 191 (1997) 603-610
39. Hoheisel U., Unger T., and Mense S. The possible role of the NO-cGMP pathway in nociception: different spinal and supraspianl action of enzyme blockers on rat dorsal horn neurones. Pain 117 (2005) 358-367
40. Honoré P., Menning P.M., Rogers S.D., Nichols M.L., Basbaum A.I., Besson J.M., and Mantyh P.W. Spinal substance P receptor expression and internalization in acute, short-term, and long-term inflammatory pain states. J. Neurosci. 19 (1999) 7670-7678
41. Ichikawa T., Ajiki K., Matsuura J., and Misawa H. Localization of two cholinergic markers, choline acetyltransferase and vesicular acetylcholine transporter in the central nervous system of the rat: in situ hybridization, histochemistry and immunohistochemistry. J. Chem. Neuroanat. 13 (1997) 23-39
42. Inglis F.M., Furia F., Zuckerman K.E., Strittmatter S.M., and Kalb R.G. The role of nitric oxide and NMDA receptors in the development of motor neuron dendrites. J. Neurosci. 18 (1998) 10493-10501
43. Inoue T., Mashimo T., Shibata M., Shibuta S., and Yoshiya I. Rapid development of nitric oxide-induced hyperalgeisa depends on an alternate to the cGMP-mediated pathway in the rat neuropathic pain model. Brain Res. 792 (1998) 263-270
44. Juilfs D.M., Fulle H.J., Zhao A.Z., Houslay M.D., Garbers D.L., and Beavo J.A. A subset of olfactory neurons that selectively express cGMP-stimulated phosphodiesterase (PDE2) and guanylyl cyclase-D define a unique olfactory signal transduction pathway. Proc. Natl. Acad. Sci. U.S.A. 94 (1997) 3388-3395
45. Kawabata A., Umeda N., and Takagi H. l-arginine exerts a dual role in nociceptive processing in the brain: involvement of the kytorphin-met-enkephalin pathway and NO-cyclic GMP pathway. Br. J. Pharmacol. 109 (1993) 73-79
46. Kim H.J., Kim M., Kim S.H., Sung J.J., and Lee K.W. Alteration in intracellular calcium homeostasis reduces motor neuronal viability expressing mutated Cu/Zn superoxide dismutase through a nitric oxide/guanylyl cyclase cGMP cascade. Neuroreport 13 (2002) 1131-1135
47. Kitto K.F., Haley J.E., and Wilcox G.L. Involvement of nitric oxide in spinally mediated hyperalgesia in the mouse. Neurosci. Lett. 148 (1992) 1-5
48. Koesling D., Russwurm M., Mergia E., Mullershausen F., and Friebe A. Nitric oxide-sensitive guanylyl cyclase: structure and regulation. Neurochem. Int. 45 (2004) 813-819
49. Komas N., Lugnier C., and Stoclet J.C. Endothelium-dependent and independent relaxation of the rat aorta by cyclic nucleotide phospodiesterase inhibitors. Br. J. Pharmacol. 104 (1991) 495-503
50. Kotera J., Yanaka N., Fujishige K., Imai Y., Akatsuka H., Ishizuka T., Kawashima K., and Omori K. Expression of rat cGMP-binding cGMP-specific phosphodiesterase mRNA in Purkinje cell layers during postnatal neuronal development. Eur. J. Biochem. 249 (1997) 434-442
51. Kotera J., Fujishige K., Michibata H., Yuasa K., Kubo A., Nakamura Y., and Omori K. Characterization and effects of methyl-2-(4-aminophenyl)-1,2-dihydro-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-3-isoquinoline carboxylate sulfate (T-1032), a novel potent inhibitor of cGMP-binding cGMP-specific phosphodiesterase (PDE5). Biochem. Pharmacol. 60 (2000) 1333-1341
52. Loughney K., Martins T.J., Harris E.A.S., Sadhu K., Hicks J.B., Sonnenburg W.K., Beavo J.A., and Ferguson K. Isolation and characterization of cDNAs corresponding to two human calcium, calmodulin-regulated, 3′,5′-cyclic nucleotide phosphodiesterases. J. Biol. Chem. 271 (1996) 796-806
53. Loughney K., Snyder P.B., Uher L., Rosman G.J., Ferguson K., and Florio V.A. Isolation and characterization of PDE10A, a novel human 3′,5′-cyclic nucleotide phosphodiesterase. Gene 234 (1999) 109-117
54. Lugnier C., Schoeffter P., Le Bec A., Strouthou E., and Stoclet J.C. Selective inhibition of cyclic nucleotide phosphodiesterases of human, bovine and rat aorta. Biochem. Pharmacol. 35 (1986) 1743-1751
55. Maihöfner C., Euchenhofer C., Tegeder I., Beck K.F., Pfeilschifter J., and Geisslinger G. Regulation and immunhistochemical localization of nitric oxide synthases and soluble guanylyl cyclase in mouse spinal cord following nociceptive stimulation. Neurosci. Lett. 290 (2000) 71-75
56. McAllister L.M., Sonnenburg W.K., Kadlecek A., Seger D., Le Trong H., Colbran J.L., Thomas M.K., Walsh K.A., Francis S.H., Corbin J.D., and Beavo J.A. The structure of a bovine lung cGMP-binding, cGMP-specific phosphodiesterase deduced from a cDNA clone. J. Biol. Chem. 268 (1993) 22863-22873
57. Meller S.T., Dykstra C., Grzybycki D., Murphy S., and Gebhart G.F. The possible role of glia in nociceptive processing and hyperalgesia in the spinal cord of the rat. Neuropharmacology 33 (1994) 1471-1478
58. Mullershausen F., Russwurm M., Friebe A., and Koesling D. Inhibition of phosphodiesterase type 5 by the activator of nitric oxide-sensitive guanylyl cyclase BAY 41-2272. Circulation 109 (2004) 1711-1713
59. Murad F. Regulation of cytosolic guanylyl cyclase by nitric oxide: the NO-cyclic GMP signal transduction system. Adv. Pharmacol. 26 (1994) 19-33
60. Nagy J.I., Yamamoto T., and Jordan L.M. Evidence for the cholinergic nature of C-terminals associated with subsurface cisterns in α-motoneurons of rat. Synapse 15 (1993) 17-32
61. Nakamizo T., Kawamata J., Yoshida K., Kawai Y., Kanki R., Sawada H., Kihara T., Yamashita H., Shibasaki H., Akaike A., and Shimohama S. Phosphodiesterase inhibitors are neuroprotective to cultured spinal motor neurons. J. Neurosci. Res. 71 (2003) 485-495
62. Nicholson C.D., Shahid M., Bruin J., Barron E., Spiers I., De Boer J., Van Amsterdam R.G.M., Zaagsma J., Kelly J.J., Dent G., Giembycz M.A., and Barnes P.J. Characterization of ORG 20241, a combined phosphodiesterase IV/III cyclic nucleotide phosphodiesterase inhibitor for asthma. J. Pharmacol. Exp. Ther. 274 (1995) 678-687
63. O'Dell T.J., Hawkins R.D., Kandel E.R., and Arancio O. Tests of the roles of two diffusible substances in long-term potentiation: evidence for nitric oxide as a possible early retrograde messenger. Proc. Natl. Acad. Sci. U.S.A. 88 (1991) 11285-11289
64. Ott S.R., Delago A., and Elphick M.R. An evolutionarily conserved mechanism for sensitization of soluble guanylyl cyclase reveals extensive nitric oxide-mediated upregulation of cyclic GMP in insect brain. Eur. J. Neurosci. 20 (2004) 1231-1244
65. Panahian N., and Maines M.D. Site of injury-directed induction of heme oxygenase-1 and -2 in experimental spinal cord injury: differential functions in neuronal defense mechanisms?. J. Neurochem. 76 (2001) 539-554
66. Patil C.S., Singh V.P., Sing S., and Kulkarni S.K. Modulatory effect of the PDE-5 inhibitor sildenafil in diabetic neuropathy. Pharmacology 72 (2004) 190-195
67. Patil C.S., Jain N.K., Singh V.P., and Kulkarni S.K. Cholinergic-NO-cGMP mediation of sildenafil-induced antinociception. Indian J. Exp. Biol. 42 (2004) 361-367
68. Pavel J., Lukáčová N., and Maršala J. Regional changes of cylic 3′,5′-guanosine monophosphate in the spinal cord of the rabbit following brief repeated ischemic insults. Neurochem. Res. 25 (2000) 1131-1137
69. Podzuweit T., Nennstiel P., and Müller A. Isozyme selective inhibition of cGMP-stimulated cyclic nucleotide phosphodiesterases by erythro-9-(2-hydroxy-3-nonyl) adenine. Cell. Signal. 7 (1995) 733-738
70. Repaske D.R., Corbin J.G., Conti M., and Goy M.F. A cyclic GMP-stimulated cyclic nucleotide phosphodiesterase gene is highly expressed in the limbic system of the rat brain. Neuroscience 56 (1993) 673-686
71. Russwurm M., and Koesling D. NO activation of guanylyl cyclase. EMBO J. 23 (2004) 4443-4450
72. Salter M., Strijbos P.J.L.M., Neale S., Duffy C., Follenfant R.L., and Garthwaite J. The nitric oxide-cyclic GMP pathway is required for nociceptive signaling at specific loci within the somatosensory pathway. Neuroscience 73 (1996) 649-655
73. Sann H., McCarthy P.W., Mäder M., and Schemann M. Choline acetyltransferase-like immunoreactivity in small diameter neurones of the rat dorsal root ganglion. Neurosci. Lett. 198 (1995) 17-20
74. Schmid H.A., and Pehl U. Regional specific effects of nitric oxide donors and cGMP on the electrical activity of neurons in the rat spinal cord. J. Chem. Neuroanat. 10 (1996) 197-201
75. Schmidt H., Werner M., Heppenstall P.A., Henning M., Moré M.I., Kühbandner S., Lewin G.R., Hofmann F., Feil R., and Rathjen F.G. cGMP-mediated signaling via cGKIα is required for the guidance and connectivity of sensory axons. J. Cell Biol. 159 (2002) 489-498
76. Schmidtko A., Ruth P., Geisslinger G., and Tegeder I. Inhibition of cyclic guanosine 5′-monophosphate-dependent protein kinase I (PKG-I) in lumbar spinal cord reduces formalin-induced hyperalgesia and PKG upregulation. Nitric Oxide 8 (2003) 89-94
77. Scholz N.L., and Truman J.W. Invertebrate models for studying NO-mediated signaling. In: Steinbusch H.W.M., de Vente J., and Vincent S.R. (Eds). Handbook of Chemical Neuroanatomy, Vol. 17: Functional Neuroanatomy of the Nitric Oxide System (2000), Elsevier Science B.V. 417-441
78. Siegan J.B., Hama A.T., and Sagen J. Alteration in rat spinal cord cGMP by peripheral nerve injury and adrenal medullary transplantation. Neurosci. Lett. 215 (1996) 49-52
79. Soderling S.H., Bayuga S.J., and Beavo J.A. Identification and characterization of a novel family of cyclic nucleotide phosphodiesterases. J. Biol. Chem. 273 (1998) 15552-15558
80. Soderling S.H., Bayuga S.J., and Beavo J.A. Isolation and characterization of a dual-substrate phosphodiesterase gene family: PDE10A. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 7071-7076
81. Sousa A.M., and Prado W.A. The dual effect of a nitric oxide donor in nociception. Brain Res. 897 (2001) 9-19
82. Southam E., and Garthwaite J. The nitric oxide-cyclic GMP signalling pathway in rat brain. Neuropharmacology 32 (1993) 1267-1277
83. Spike R.C., Todd A.J., and Johnston H.W. Coexistence of NADPH diaphorase with GABA, glycine, and acetylcholine in rat spinal cord. J. Comp. Neurol. 335 (1993) 320-333
84. Stasch J.P., Becker E.M., Alonso-Alija C., Apeler H., Dembowsky K., Feurer A., Gerzer R., Minuth T., Perzborn E., Pleiss U., Schröder H., Schroeder W., Stahl E., Steinke W., Straub A., and Schramm M. NO-independent regulatory site on soluble guanylate cyclase. Nature 410 (1991) 212-215
85. Tamura N., Chrisman T.D., and Garbers D.L. The regulation and physiological roles of the guanylyl cyclase receptors. Endocr. J. 48 (2001) 611-634
86. Tanaka J., Markerink-van Ittersum M., Steinbusch H.W.M., and De Vente J. Nitric oxide-mediated cGMP synthesis in oligodendrocytes in the developing rat brain. Glia 19 (1997) 286-297
87. Tao Y.X., Haddad H.E., and Johns R.A. Expression and action of cyclic GMP-dependent protein kinase Iα in inflammatory hyperalgesia in rat spinal cord. Neuroscience 95 (2000) 525-533
88. Tao Y.X., and Johns R.A. Activation and up-regulation of spinal cord nitric oxide receptor, soluble guanylate cyclase, after formalin injection into the rat hind paw. Neuroscience 11 (2002) 439-446
89. Tegeder I., Schmidtko A., Niederberger E., Ruth P., and Geisslinger G. Dual effects of spinally delivered 8-bromo-cyclic guanosine monophosphate (8-bromo-cGMP) in formalin-induced nociception in rats. Neurosci. Lett. 332 (2002) 146-150
90. Tegeder I., Del Turco D., Schmidtko A., Sausbier M., Feil R., Hofmann F., Deller T., Ruth P., and Geisslinger G. Reduced inflammatory hyperalgesia with preservation of acute thermal nociception in mice lacking cGMP-dependent protein kinase I. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 3253-3257
91. Thompson W.J. Cyclic nucleotide phosphodiesterases: pharmacology, biochemistry and function. Pharmacol. Ther. 51 (1991) 13-33
92. Urushitani M., Shimahama S., Kihara T., Sawada H., Akaike A., Ibi M., Inoue R., Kitamura Y., Taniguchi T., and Kimura J. Mechanism of selective motor neuronal death after exposure of spinal cord to glutamate: involvement of glutamate-induced nitric oxide in motor neuron toxicity and nonmotor neuron protection. Ann. Neurol. 44 (1998) 796-807
93. Valtschanoff J.G., Weinberg R.J., and Rustioni A. NADPH diaphorase in the spinal cord of rats. J. Comp. Neurol. 321 (1992) 209-222
94. Van Staveren W.C.G., Glick J., Markerink-van Ittersum M., Shimizu M., Beavo J.A., Steinbusch H.W.M., and De Vente J. Cloning and localization of the cGMP-specific phosphodiesterase type 9 in the rat brain. J. Neurocytol. 31 (2002) 729-741
95. Van Staveren W.C.G., Steinbusch H.W.M., Markerink-van Ittersum M., Repaske D.R., Goy M.F., Kotera J., Omori K., Beavo J.A., and De Vente J. mRNA expression patterns of the cGMP-hydrolyzing phosphodiesterases types 2, 5, and 9 during development of the rat brain. J. Comp. Neurol. 467 (2003) 566-580
96. Van Staveren W.C.G., Markerink-van Ittersum M., Steinbusch H.W.M., Behrends S., and De Vente J. Localization and characterization of cGMP-immunoreactive structures in rat brain slices after NO-dependent and NO-independent stimulation of soluble guanylyl cyclase. Brain Res. 1036 (2005) 77-89
97. Vincent S.R., and Kimura H. Histochemical mapping of nitric oxide synthase in the rat brain. Neuroscience 46 (1992) 755-784
98. Vles J.S.H., De Louw A.J., Steinbusch H., Markerink-van Ittersum M., Steinbusch H.W.M., Blanco C.E., Axer H., Troost J., and De Vente J. Localization and age-related changes of nitric oxide- and ANP-mediated cyclic-GMP synthesis in rat cervical spinal cord: an immunocytochemical study. Brain Res. 857 (2000) 219-234
99. Wang H.G., Lu F.M., Jin I., Udo H., Kandel E.R., De Vente J., Walter U., Lohmann S.M., Hawkins R.D., and Antonova I. Presynaptic roles of NO, cGK, and RhoA in long-lasting potentiation and aggregation of synaptic proteins. Neuron 45 (2005) 389-403
100. Weruaga E., Alonso J.R., Porteros A., Crespo C., Arevalo R., Briñón, Velasco A., and Aijón J. Nonspecific labeling of myelin with secondary antisera and high concentrations of Triton X-100. J. Histochem. Cytochem. 46 (1998) 109-117
101. Wilson J.M., Rempel J., and Brownstone R.M. Postnatal development of cholinergic synapses on mouse spinal motoneurons. J. Comp. Neurol. 474 (2004) 13-23
102. Wu C.C., Ko F.N., Kuo S.C., Lee F.Y., and Teng C.M. YC-1 inhibited human platelet aggregation through NO-independent activation of soluble guanylate cyclase. Br. J. Pharmacol. 116 (1995) 1973-1978
103. Wu J., Lin Q., Lu Y., Willis W.D., and Westlund K.N. Changes in nitric oxide synthase isoforms in the spinal cord of rat following induction of chronic arthritis. Exp. Brain Res. 118 (1998) 457-465
104. Wu Y., Li Y., Liu H., and Wu W. Induction of nitric oxide synthase and motoneuron death in newborn and early postnatal rats following spinal root avulsion. Neurosci. Lett. 194 (1995) 109-112
105. Wunder F., Tersteegen A., Rebmann, Erb C., Fahrig T., and Mendrix M. Characterization of the first potent and selective PDE9 inhibitor using a cGMP reporter cell line. Mol. Pharmacol. 68 (2005) 1775-1781
106. Yoon M.H., Choi J.I., Bae H.B., Jeong S.W., Chung S.S., Yoo K.Y., Jeong C.Y., Kim S.J., Chung S.T., and Kim C.M. Lack of the nitric oxide-cyclic GMP-potassium channel pathway for the antinociceptive effect of intrathecal zaprinast in a rat formalin test. Neurosci. Lett. 390 (2005) 114-117
107. Yu S.M., Cheng Z.J., and Kuo S.C. Endothelium-dependent relaxation of rat aorta by butein, a novel cyclic AMP-specific phosphodiesterase inhibitor. Eur. J. Pharmacol. 280 (1995) 69-77
108. Yu J., Wolda S.L., Frazier A.L.B., Florio V.A., Martins T.J., Snyder P.B., Harris E.A.S., McCaw K.N., Farrell C.A., Steiner B., Bentley J.K., Beavo J.A., Ferguson K., and Gelinas R. Identification and characterisation of a human calmodulin-stimulated phosphodiesterase PDE1B1. Cell. Signal. 9 (1997) 519-529
109. Zhang X., Verge V., Wiesenfeld-Hallin Z., Ju G., Bredt D., Snyder S.H., and Hökfelt T. Nitric oxide synthase-like immunoreactivity in lumbar dorsal root ganglia and spinal cord of rat and monkey and effect of peripheral axotomy. J. Comp. Neurol. 335 (1993) 563-575